Fig. 3. Effect of combining BRAF inhibitors with BH3 mimetics on apoptosis in BRAFV600E CRC cell lines.
BRAFV600E CRC cell lines were treated with encorafenib (100 nM) alone and in combination with either (A) the MCL-1 inhibitor S63845 (1 μM), (B) the BCL-XL inhibitor A-1331852 (10 nM) or (C) the BCL-2 inhibitor ABT-199 (1 μM) for 72 h and apoptosis induction determined by PI staining and FACS analysis. Values shown are mean ± SEM from a representative experiment performed in technical triplicates. Differences between groups were compared using one-way ANOVA with Tukey’s multiple comparison testing; ns (not significant), *(p ≤ 0.05), ***(p ≤ 0.001) and ****(p ≤ 0.0001).